Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Nature Communications|December 24, 2025
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapyKedan Gu, Ting Liang, Luting Hu, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 13, 2021
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide InhibitorPierre Morissette, Nianyu Li, Jeanine E Ballard, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-oneHaifeng Tang, Reynald K de Jesus, Shawn P Walsh, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism DiureticsHaifeng Tang, Shawn P Walsh, Yan Yan, et al.
Bioorganic & Medicinal Chemistry Letters|March 28, 2016
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporationShawn P Walsh, Aurash Shahripour, Haifeng Tang, et al.
Cancer|December 9, 2025
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trialJun Zhang, Yanqiao Zhang, Haibo Qiu, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart FailureHaifeng Tang, Yuping Zhu, Nardos Teumelsan, et al.
Bioorganic & Medicinal Chemistry Letters|February 11, 2017
Discovery of phenyl acetamides as potent and selective GPR119 agonistsCheng Zhu, Liping Wang, Yuping Zhu, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II DiabetesPing Liu, Zhiyong Hu, Byron G DuBois, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2023
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in ChinaJian Li, Jun Zhang, Yanqiao Zhang, et al.
Pageof 14